Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ESSA Pharma ( (EPIX) ) has shared an update.
On September 30, 2025, ESSA Pharma Inc. announced that it received an amended Interim Order from the Supreme Court of British Columbia related to its Business Combination Agreement with XenoTherapeutics Inc. The order approves the dates for ESSA’s special meeting and court hearing concerning the acquisition of ESSA by XenoTherapeutics, a non-profit biotechnology company. This development is a significant step in the acquisition process, potentially impacting ESSA’s operations and market positioning.
The most recent analyst rating on (EPIX) stock is a Hold with a $2.25 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.
Spark’s Take on EPIX Stock
According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPIX stock, click here.
More about ESSA Pharma
ESSA Pharma Inc. is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Average Trading Volume: 6,406,897
Technical Sentiment Signal: Sell
Current Market Cap: $9.15M
Find detailed analytics on EPIX stock on TipRanks’ Stock Analysis page.